Xbrane Biopharma AB (publ) filed its Annual on Mar 31, 2023 for the period ending Dec 31, 2022. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2295 SEK | +20.54% | +13.61% | -97.70% |
02:43pm | Xbrane Biopharma, Stada Sign US Licensing Deal for Lucentis Biosimilar | MT |
05-02 | Xbrane Biopharma AB Appoints Kristoffer Bissessar Was Elected as New Director | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-97.70% | 26.8M | |
+18.01% | 47.02B | |
+48.77% | 41.86B | |
+0.44% | 41.76B | |
-4.27% | 28.8B | |
+11.85% | 26.05B | |
-22.22% | 19.15B | |
+4.46% | 12.55B | |
+29.31% | 12.34B | |
-3.92% | 11.82B |
- Stock Market
- Equities
- XBRANE Stock
- News Xbrane Biopharma AB
- Xbrane Biopharma AB Auditor Raises 'Going Concern' Doubt